Abdominelle Sonografie bei Patienten mit Diabetes mellitus. Teil 1: Leber

C. Jenssen; C. Pietsch; U. Gottschalk; A. P. Barreiros; A. Teufel; X. W. Cui; C. F. Dietrich

doi:10.1055/s-0034-1398949

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2015; 53(04): 306-319
DOI: 10.1055/s-0034-1398949

Übersicht

Abdominelle Sonografie bei Patienten mit Diabetes mellitus. Teil 1: Leber

Abdominal ultrasonography in patients with diabetes mellitus. Part 1: Liver

C. Jenssen

¹Innere Medizin, Krankenhaus Märkisch Oderland GmbH, Strausberg

,

C. Pietsch

¹Innere Medizin, Krankenhaus Märkisch Oderland GmbH, Strausberg

,

U. Gottschalk

²Klinik für Gastroenterologie, Vivantes-Klinikum am Friedrichshain, Berlin

,

A. P. Barreiros

³Med. Klinik, Universität Regensburg

,

A. Teufel

³Med. Klinik, Universität Regensburg

,

X. W. Cui

⁴Med. Klinik 2, Caritas-Krankenhaus Bad Mergentheim

,

C. F. Dietrich

⁴Med. Klinik 2, Caritas-Krankenhaus Bad Mergentheim

› Author Affiliations

Abstract

Zusammenfassung

Die abdominelle Sonografie ist geeignet, Folgeschäden und Begleiterkrankungen des Diabetes mellitus an Leber, Pankreas, Nieren, Gastrointestinaltrakt und abdominell-retroperitonealen arteriellen Gefäßen zu erfassen und zu verfolgen. Darüber hinaus ermöglicht die abdominelle Sonografie die Erfassung von Pankreas- und Lebererkrankungen, die ursächlich für einen Diabetes mellitus sind. Auf der Grundlage einer systematischen Literaturanalyse wird in einer 3-teiligen Übersichtsarbeit der Stellenwert der abdominellen Sonografie bei Patienten mit Diabetes mellitus dargestellt. Teil 1 beschreibt die Relevanz und konkrete Befunde sonografischer Methoden für die Diagnostik der hepatischen Manifestationen und Komplikationen des Diabetes mellitus.

Abstract

In patients with diabetes mellitus, abdominal ultrasonography is the appropriate diagnostic technique to detect and to follow-up secondary and accompanying diseases of the liver, the kidneys, the pancreas, the gastrointestinal tract and of abdominal vessels. Moreover, pancreatic and hepatic diseases may be realized which are of etiological importance for diabetes mellitus. Based on a systematic survey of the published literature, this review in 3 parts will describe the value of abdominal ultrasonography in patients with diabetes mellitus. Part 1 deals with the diagnostic relevance and particular findings of ultrasonographic methods in hepatic manifestations and complications of diabetes mellitus.

Schlüsselwörter

Diabetes mellitus - nicht alkoholische Fettlebererkrankung (NAFLD) - Leberzirrhose - Glykogen-Hepatopathie - hepatozelluläres Karzinom - abdominelle Sonografie - Elastografie

Key words

diabetes mellitus - nonalcoholic fatty liver disease (NAFLD) - liver cirrhosis - glykogenic hepatopathy - hepatocellular carcinoma - abdominal ultrasonography - elastography

Full Text

References

Literatur
1 Heidemann C, Du Y, Schubert I et al. Prevalence and temporal trend of known diabetes mellitus: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 668-677
2 Rathmann W, Scheidt-Nave C, Roden M et al. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 2013; 110: 331-337
3 Seshasai SR, Kaptoge S, Thompson A. Emerging Risk Factors C et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841
4 Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes 2014; 5: 372-380
5 Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21: 273-280
6 Bytzer P, Talley NJ, Leemon M et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15 000 adults. Arch Intern Med 2001; 161: 1989-1996
7 Xue Y, Sheng Y, Dai H et al. Risk of development of acute pancreatitis with pre-existing diabetes: a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24: 1092-1098
8 Dietrich CF, Mäurer M, Riemer-Hommel P. Challenges for the German Health Care System – Pharmaceuticals. Endoskopie heute 2014; 27: 45-53
9 Dietrich CF, Riemer-Hommel P. Challenges for the German Health Care System. Z Gastroenterol 2012; 50: 557-572
10 Schuler A, Reuss J, Delorme S et al. Costs of clinical ultrasound examinations – an economical cost calculation and analysis. Ultraschall in Med 2010; 31: 379-386
11 Nurnberg D, Jung A, Schmieder C et al. What's the price of routine sonography--results of an analysis of costs and processes in a district hospital. Ultraschall in Med 2008; 29: 405-417
12 Jaeckel E, Taubert R, Manns MP. Leber und Diabetes. Der Diabetologe 2014; 10: 405-417
13 Leite NC, Villela-Nogueira CA, Cardoso CR et al. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20: 8377-8392
14 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285
15 Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
16 Weiss J, Rau M, Geier A. Non-alcoholic Fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014; 111: 447-452
17 Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract 2014; 104: 53-62
18 Gundling F, Schepp W. Diabetes und Leberzirrhose. Der Diabetologe 2013; 9: 541-550
19 Gundling F, Schumm-Draeger PM, Schepp W. [Hepatogenous diabetes – diagnostics and treatment]. Z Gastroenterol 2009; 47: 436-445
20 Creighton MitchellT, McClain DA. Diabetes and hemochromatosis. Curr Diab Rep 2014; 14: 488
21 Williams KH, Shackel NA, Gorrell MD et al. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev 2013; 34: 84-129
22 Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384
23 Targher G, Bertolini L, Padovani R et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718
24 Stepanova M, Rafiq N, Makhlouf H et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013; 58: 3017-3023
25 Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-1745
26 Musso G, Gambino R, Cassader M et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649
27 Choi JH, Rhee EJ, Bae JC et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44: 115-120
28 Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. World J Gastroenterol 2013; 19: 3375-3384
29 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1712-1723
30 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age?. World J Gastroenterol 2014; 20: 9072-9089
31 Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395
32 Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292
33 Verma S, Jensen D, Hart J et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013; 33: 1398-1405
34 Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798
35 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007-1019
36 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-485
37 Fedchuk L, Nascimbeni F, Pais R et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1209-1222
38 Zelber-Sagi S, Webb M, Assy N et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013; 19: 57-64
39 Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 6821-6825
40 Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750
41 Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090
42 Palmentieri B, de Sio I, La Mura V et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485-489
43 Mathiesen UL, Franzen LE, Aselius H et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34: 516-522
44 Webb M, Yeshua H, Zelber-Sagi S et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. Am J Roentgenol 2009; 192: 909-914
45 Marshall RH, Eissa M, Bluth EI et al. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. Am J Roentgenol 2012; 199: 997-1002
46 Mancini M, Prinster A, Annuzzi G et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009; 58: 1724-1730
47 Borges VF, Diniz AL, Cotrim HP et al. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J Clin Ultrasound 2013; 41: 18-25
48 Wong GL. Transient elastography: Kill two birds with one stone?. World J Hepatol 2013; 5: 264-274
49 Shi KQ, Tang JZ, Zhu XL et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29: 1149-1158
50 Myers RP, Pollett A, Kirsch R et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-910
51 Karlas T, Petroff D, Garnov N et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014; 9: e91987
52 de Ledinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014; 60: 1026-1031
53 Carvalhana S, Leitao J, Alves AC et al. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2014; 34: e111-117
54 Sasso M, Beaugrand M, de Ledinghen V et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835
55 Xia MF, Yan HM, He WY et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 2012; 20: 444-452
56 von Volkmann HL, Havre RF, Loberg EM et al. Quantitative measurement of ultrasound attenuation and Hepato-Renal Index in Non-Alcoholic Fatty Liver Disease. Med Ultrason 2013; 15: 16-22
57 Dietrich CF. Leber. In: Dietrich CF, , ed. Ultraschall-Kurs. Organbezogene Darstellung von Grund-, Aufbau- und Abschlusskurs. Nach den Richtlinien von KBV, DEGUM, ÖGUM und SGUM. Köln: Deutscher Ärzte-Verlag; 2012: 51-101
58 Dasarathy S, Dasarathy J, Khiyami A et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061-1067
59 Hamaguchi M, Kojima T, Itoh Y et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715
60 Bernatik T. Diffuse Leberveränderungen. In: Seitz K, Schuler A, Rettenmaier G, , eds. Klinische Sonographie und sonographische Differenzialdiagnose. Volume 1. Stuttgart, New York: Georg Thieme Verlag; 2008: 23 -72
61 Hirche TO, Ignee A, Hirche H et al. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007; 27: 748-757
62 Dietrich CF, Schall H, Kirchner J et al. Sonographic detection of focal changes in the liver hilus in patients receiving corticosteroid therapy. Z Gastroenterol 1997; 35: 1051-1057
63 Dietrich CF, Lee JH, Gottschalk R et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. Am J Roentgenol 1998; 171: 437-443
64 Mohammadinia AR, Bakhtavar K, Ebrahimi-Daryani N et al. Correlation of hepatic vein Doppler waveform and hepatic artery resistance index with the severity of nonalcoholic fatty liver disease. J Clin Ultrasound 2010; 38: 346-352
65 Solhjoo E, Mansour-Ghanaei F, Moulaei-Langorudi R et al. Comparison of portal vein doppler indices and hepatic vein doppler waveform in patients with nonalcoholic fatty liver disease with healthy control. Hepat Mon 2011; 11: 740-744
66 Topal NB, Orcan S, Sigirli D et al. Effects of fat accumulation in the liver on hemodynamic variables assessed by doppler ultrasonography. J Clin Ultrasound 2015; 43: 26-33
67 Gaiani S, Avogaro A, Bombonato GC et al. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography(). J Ultrasound 2009; 12: 1-5
68 Lin SC, Heba E, Wolfson T et al. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clin Gastroenterol Hepatol 2014; Dec 3; Epub ahead of print
69 Li X, Xia M, Ma H et al. Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. PLoS One 2013; 8: e65210
70 Ballestri S, Lonardo A, Romagnoli D et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012; 32: 1242-1252
71 Kratzer W, Akinli AS, Bommer M et al. Prevalence and risk factors of focal sparing in hepatic steatosis. Ultraschall in Med 2010; 31: 37-42
72 Zardi EM, De Sio I, Ghittoni G et al. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis?. J Clin Gastroenterol 2011; 45: 59-63
73 Tarantino G, Scalera A, Finelli C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J Gastroenterol 2013; 19: 3534-3542
74 Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci 2000; 45: 196-200
75 Suzuki K, Kirikoshi H, Yoneda M et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res 2010; 40: 693-700
76 Tarantino G, Conca P, Pasanisi F et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur J Gastroenterol Hepatol 2009; 21: 504-511
77 Iijima H, Moriyasu F, Tsuchiya K et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 722-730
78 Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014; 6: 496-503
79 D'Onofrio M, Martone E, Brunelli S et al. Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. Radiol Med 2005; 110: 341-348
80 Allan R, Thoirs K, Phillips M. Accuracy of ultrasound to identify chronic liver disease. World J Gastroenterol 2010; 16: 3510-3520
81 Shen L, Li JQ, Zeng MD et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006; 12: 1292-1295
82 Cao G, Shi P, Hu B. Liver fibrosis identification based on ultrasound images. Conf Proc IEEE Eng Med Biol Soc 2005; 6: 6317-6320
83 Jeong JW, Lee S, Lee JW et al. The echotextural characteristics for the diagnosis of the liver cirrhosis using the sonographic images. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 1343-1345
84 Yeh WC, Huang SW, Li PC. Liver fibrosis grade classification with B-mode ultrasound. Ultrasound Med Biol 2003; 29: 1229-1235
85 Toyoda H, Kumada T, Kamiyama N et al. B-mode ultrasound with algorithm based on statistical analysis of signals: evaluation of liver fibrosis in patients with chronic hepatitis C. Am J Roentgenol 2009; 193: 1037-1043
86 Ricci P, Marigliano C, Cantisani V et al. Ultrasound evaluation of liver fibrosis: preliminary experience with acoustic structure quantification (ASQ) software. Radiol Med 2013; 118: 995-1010
87 Kuroda H, Kakisaka K, Kamiyama N et al. Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude. World J Gastroenterol 2012; 18: 3889-3895
88 Moon KM, Kim G, Baik SK et al. Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clin Mol Hepatol 2013; 19: 389-398
89 Zhang L, Li QY, Duan YY et al. Artificial neural network aided non-invasive grading evaluation of hepatic fibrosis by duplex ultrasonography. BMC Med Inform Decis Mak 2012; 12: 55
90 Lutz HH, Gassler N, Tischendorf FW et al. Doppler ultrasound of hepatic blood flow for noninvasive evaluation of liver fibrosis compared with liver biopsy and transient elastography. Dig Dis Sci 2012; 57: 2222-2230
91 Dietrich CF, Averkiou MA, Correas JM et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall in Med 2012; 33: 344-351
92 Ying M, Leung G, Lau TY et al. Evaluation of liver fibrosis by investigation of hepatic parenchymal perfusion using contrast-enhanced ultrasound: an animal study. J Clin Ultrasound 2012; 40: 462-470
93 Kaneko T, Teshigawara O, Sugimoto H et al. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver. Liver Int 2005; 25: 288-293
94 Ishibashi H, Maruyama H, Takahashi M et al. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography. Liver Int 2010; 30: 1355-1363
95 Orlacchio A, Bolacchi F, Petrella MC et al. Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results. Ultrasound Med Biol 2011; 37: 1-6
96 Tang A, Kim TK, Heathcote J et al. Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis?. Ultrasound Med Biol 2011; 37: 1963-1969
97 Staub F, Tournoux-Facon C, Roumy J et al. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009; 19: 1991-1997
98 Li N, Ding H, Fan P et al. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol 2010; 36: 1066-1075
99 Cosgrove D, Piscaglia F, Bamber J et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications. Ultraschall in Med 2013; 34: 238-253
100 Bamber J, Cosgrove D, Dietrich CF et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall in Med 2013; 34: 169-184
101 Ochi H, Hirooka M, Koizumi Y et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56: 1271-1278
102 Nobili V, Vizzutti F, Arena U et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-448
103 Orlacchio A, Bolacchi F, Antonicoli M et al. Liver elasticity in NASH patients evaluated with real-time elastography (RTE). Ultrasound Med Biol 2012; 38: 537-544
104 Wong GL, Wong VW, Choi PC et al. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-1103
105 Palmeri ML, Wang MH, Rouze NC et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-672
106 Casey SP, Kemp WW, McLean CA et al. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol 2012; 47: 836-841
107 Friedrich-Rust M, Romen D, Vermehren J et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-331
108 Sporea I, Bota S, Jurchis A et al. Acoustic radiation force impulse and supersonic shear imaging versus transient elastography for liver fibrosis assessment. Ultrasound Med Biol 2013; 39: 1933-1941
109 Sporea I, Jurchis A, Sirli R et al. Can transient elastography be a reliable method for assessing liver fibrosis in non alcoholic steatohepatitis (NASH)?. Med Ultrason 2013; 15: 106-110
110 Kumar R, Rastogi A, Sharma MK et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013; 58: 265-274
111 Cassinotto C, Lapuyade B, Mouries A et al. Non-invasive assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol 2014; 61: 550-557
112 Kwok R, Tse YK, Wong GL et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-269
113 Bota S, Herkner H, Sporea I et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33: 1138-1147
114 Sporea I. Why, who and how should perform liver biopsy in chronic liver diseases. World Journal of Gastroenterology 2008; 14: 3396
115 Nalbantoglu I, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 9026-9037
116 Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906
117 Merriman RB, Ferrell LD, Patti MG et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880
118 El-Badry AM, Breitenstein S, Jochum W et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-697
119 Jenssen C, Dietrich CF. Kontraindikationen, Komplikationen, Komplikationsmanagement. In: Dietrich CF, Nürnberg D, eds. Interventioneller Ultraschall. Lehrbuch und Atlas für die interventionelle Sonographie. Stuttgart, New York: Georg Thieme Verlag; 2011: 127-160
120 Strobel D, Mueller T, Reichel A et al. Spectrum and complications of percutaneous ultrasound guided intraabdominal interventions – results of the prospective multicenter DEGUM study (abstract). Ultraschall in Med 2013; 34: WS_SL8_02
121 Silva MA, Hegab B, Hyde C et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596
122 Terjung B, Lemnitzer I, Dumoulin FL et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 138-145
123 Festi D, Schiumerini R, Marzi L et al. Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400
124 Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
125 Angulo P, Bugianesi E, Bjornsson ES et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789 e784
126 Rinella ME, Loomba R, Caldwell SH et al. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 2014; 10: 219-227
127 Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28: 650-658
128 Strauss S, Gavish E, Gottlieb P et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007; 189: W320-323
129 Mottin CC, Moretto M, Padoin AV et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14: 635-637
130 de Moura AlmeidaA, Cotrim HP, Barbosa DB et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14: 1415-1418
131 Liang RJ, Wang HH, Lee WJ et al. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 2007; 17: 45-56
132 Hediger S, Preller V, Jochum W et al. Glykogen-Hepatopathie bei Diabetes mellitus Typ 1. Forum Med Suisse 2010; 10: 510-512
133 Murata F, Horie I, Ando T et al. A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI. Endocr J 2012; 59: 669-676
134 Pozzato C, Curti A, Radaelli G et al. Abdominal ultrasonography in inheredited diseases of carbohydrate metabolism. Radiol Med 2005; 109: 139-147
135 Lee P, Mather S, Owens C et al. Hepatic ultrasound findings in the glycogen storage diseases. Br J Radiol 1994; 67: 1062-1066
136 Schwenzer NF, Springer F, Schraml C et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445
137 Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7392-7402
138 Bohte AE, van Werven JR, Bipat S et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011; 21: 87-97
139 Torbenson M, Chen YY, Brunt E et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006; 30: 508-513
140 Barreiros AP, Chiorean L, Braden B et al. Ultrasound in Rare Diffuse Liver Disease. Z Gastroenterol 2014; 52: 1247-1256
141 Ramakrishna R, Gupta S, Sarathy K et al. Phenotypic and clinical manifestations of compound heterozygous genetic haemochromatosis (CHGH): a non-invasive approach to clinical management. Intern Med J 2013; 43: 254-261
142 Adams LA, Harmsen S, St SauverJL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-1573
143 Wang C, Wang X, Gong G et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012; 130: 1639-1648
144 Wang P, Kang D, Cao W et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28: 109-122
145 Lai SW, Chen PC, Liao KF et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52
146 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359 e1342
147 Onnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol 2014; 1-8
148 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665
149 Bhala N, Angulo P, van der Poorten D et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216
150 Dyson J, Jaques B, Chattopadyhay D et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117
151 Schutte K, Kipper M, Kahl S et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion 2013; 87: 147-159
152 Huang YW, Yang SS, Fu SC et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. Hepatology 2014; 60: 807-814
153 Chen J, Han Y, Xu C et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev 2015; 24: 89-99
154 Huo TI, Hsu CY, Huang YH et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010; 30: 198-207
155 Connolly GC, Safadjou S, Chen R et al. Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma. Cancer Invest 2012; 30: 698-702
156 Wang WM, Xu Y, Yang XR et al. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis. Hepatobiliary Pancreat Dis Int 2011; 10: 346-355
157 Berzigotti A, Piscaglia F, Education E et al. Ultrasound in portal hypertension – part 2 – and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension. Ultraschall in Med 2012; 33: 8-32 ; quiz 30-31
158 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20: 4300-4315
159 Friedrich-Rust M, Buggisch P, de Knegt RJ et al. Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B. J Viral Hepat 2013; 20: 240-247
160 Cui XW, Friedrich-Rust M, De Molo C et al. Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol 2013; 19: 6329-6347
161 Sporea I, Sirli RL. Hepatic elastography for the assessment of liver fibrosis – present and future. Ultraschall in Med 2012; 33: 550-558
162 Singh S, Fujii LL, Murad MH et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1573-1584 e1571-1572; quiz e1588-1579
163 Greten TF, Malek NP, Schmidt S et al. Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 2013; 51: 1269-1326
164 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11: e1001624
165 Claudon M, Dietrich CF, Choi BI et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver – update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall in Med 2013; 34: 11-29
166 Gaiani S, Gramantieri L, Venturoli N et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-985
167 Aube C, Winkfield B, Oberti F et al. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol 2004; 16: 743-751
168 Aube C, Oberti F, Korali N et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-478
169 Dietrich CF, Sharma M, Gibson RN et al. Fortuitously discovered liver lesions. World J Gastroenterol 2013; 19: 3173-3188
170 Dietrich CF, Jenssen C. Focal liver lesion, incidental finding. Dtsch Med Wochenschr 2012; 137: 2099-2116
171 Seitz K, Greis C, Schuler A et al. Frequency of tumor entities among liver tumors of unclear etiology initially detected by sonography in the noncirrhotic or cirrhotic livers of 1349 patients. Results of the DEGUM multicenter study. Ultraschall in Med 2011; 32: 598-603
172 Ignee A, Weiper D, Schuessler G et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z Gastroenterol 2005; 43: 289-294
173 Rapaccini GL, Pompili M, Caturelli E et al. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004; 24: 124-130
174 Livraghi T, Sangalli G, Giordano F et al. 240 hepatocellular carcinomas: ultrasound features, tumor size, cytologic and histologic patterns, serum alpha-fetoprotein and HBs Ag. Tumori 1987; 73: 507-512
175 Loria F, Loria G, Basile S et al. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation between enhancement pattern and cellular differentiation on histopathlogy. Updates Surg 2012; 64: 247-255
176 Pei XQ, Liu LZ, Liu M et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma: correlation between quantitative parameters and histological grading. Br J Radiol 2012; 85: e740-e747
177 Liu GJ, Xu HX, Lu MD et al. Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumour cellular differentiation on histopathology. Br J Radiol 2007; 80: 321-330
178 Dietrich CF, Cui XW, Boozari B et al. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultraschall in Med 2012; 33 (Suppl. 01) S57-66
179 Boozari B, Soudah B, Rifai K et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography – a prospective study. Dig Liver Dis 2011; 43: 484-490
180 Xu HX, Lu MD, Liu LN et al. Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound. Br J Radiol 2012; 85: 1376-1384
181 Leoni S, Piscaglia F, Granito A et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?. Ultraschall in Med 2013; 34: 280-287
182 de Sio I, Iadevaia MD, Vitale LM et al. Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. United European Gastroenterol J 2014; 2: 279-287
183 Kim TK, Jang HJ. Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis. World J Gastroenterol 2014; 20: 3590-3596
184 von Herbay A, Vogt C, Westendorff J et al. Correlation between SonoVue enhancement in CEUS, HCC differentiation and HCC diameter: analysis of 130 patients with hepatocellular carcinoma (HCC). Ultraschall in Med 2009; 30: 544-550
185 Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47
186 Singal AG, Conjeevaram HS, Volk ML et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-799
187 Dietrich CF, Ignee A, Greis C et al. Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall in Med 2014; 35: 108-125 ; quiz 126-107
188 Dietrich CF, Ignee A, Hocke M et al. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol 2011; 49: 350-356
189 Niu Y, Huang T, Lian F et al. Contrast-enhanced ultrasonography for the diagnosis of small hepatocellular carcinoma: a meta-analysis and meta-regression analysis. Tumour Biol 2013; 34: 3667-3674
190 Caturelli E, Solmi L, Anti M et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004; 53: 1356-1362
191 Kudo M, Zheng RQ, Kim SR et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 2008; 51 (Suppl. 01) 17-26
192 Wang QB, Zhu H, Liu HL et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012; 56: 239-247